153 related articles for article (PubMed ID: 9430481)
1. False-positive somatostatin receptor scintigraphy due to an accessory spleen.
Lebtahi R; Cadiot G; Marmuse JP; Vissuzaine C; Petegnief Y; Courillon-Mallet A; Cattan D; Mignon M; Le Guludec D
J Nucl Med; 1997 Dec; 38(12):1979-81. PubMed ID: 9430481
[TBL] [Abstract][Full Text] [Related]
2. What is a false-positive somatostatin receptor scintigraphy?
Reubi JC
J Nucl Med; 1998 Dec; 39(12):2193-4. PubMed ID: 9867170
[No Abstract] [Full Text] [Related]
3. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas.
Gibril F; Reynolds JC; Chen CC; Yu F; Goebel SU; Serrano J; Doppman JL; Jensen RT
J Nucl Med; 1999 Apr; 40(4):539-53. PubMed ID: 10210211
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison.
de Kerviler E; Cadiot G; Lebtahi R; Faraggi M; Le Guludec D; Mignon M
Eur J Nucl Med; 1994 Nov; 21(11):1191-7. PubMed ID: 7859770
[TBL] [Abstract][Full Text] [Related]
5. Making the best of imperfect tumor-localizing radiopharmaceuticals.
Shapiro B; Gross MD
J Nucl Med; 1999 Apr; 40(4):554-5. PubMed ID: 10210212
[No Abstract] [Full Text] [Related]
6. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study.
Gibril F; Reynolds JC; Doppman JL; Chen CC; Venzon DJ; Termanini B; Weber HC; Stewart CA; Jensen RT
Ann Intern Med; 1996 Jul; 125(1):26-34. PubMed ID: 8644985
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostic value of somatostatin receptor scintigraphy with indium-111 pentetreotide in small-cell bronchial carcinoma].
Hoefer M; Schmidt S; Welter J; Kirsch CM; Ukena D; Sybrecht GW
Pneumologie; 1998 Feb; 52(2):106-12. PubMed ID: 9557059
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
[TBL] [Abstract][Full Text] [Related]
9. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system].
Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO
Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450
[TBL] [Abstract][Full Text] [Related]
10. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
[TBL] [Abstract][Full Text] [Related]
11. Tc-99m red blood cell uptake in positive somatostatin receptor scintigraphy by two accessory spleens.
Martínez-Rodríguez I; Allende RH; Banzo I; Quirce R; Jiménez-Bonilla J; Sainz-Esteban A; Carril JM
Clin Nucl Med; 2006 Jun; 31(6):340-1. PubMed ID: 16714895
[No Abstract] [Full Text] [Related]
12. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
13. Preoperative localization of gastrointestinal endocrine tumors using somatostatin-receptor scintigraphy.
Weinel RJ; Neuhaus C; Stapp J; Klotter HJ; Trautmann ME; Joseph K; Arnold R; Rothmund M
Ann Surg; 1993 Nov; 218(5):640-5. PubMed ID: 7902072
[TBL] [Abstract][Full Text] [Related]
14. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors.
Schillaci O; Scopinaro F; Angeletti S; Tavolaro R; Danieli R; Annibale B; Gualdi G; Delle Fave G
J Nucl Med; 1996 Sep; 37(9):1452-6. PubMed ID: 8790191
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
[TBL] [Abstract][Full Text] [Related]
16. Factor analysis of dynamic series (FADS) in somatostatin receptor imaging.
Kolesnikov-Gauthier H; Huglo D; Nocaudie M; Marchandise X
J Nucl Med; 1999 Jan; 40(1):33-9. PubMed ID: 9935053
[TBL] [Abstract][Full Text] [Related]
17. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.
Lebtahi R; Le Cloirec J; Houzard C; Daou D; Sobhani I; Sassolas G; Mignon M; Bourguet P; Le Guludec D
J Nucl Med; 2002 Jul; 43(7):889-95. PubMed ID: 12097458
[TBL] [Abstract][Full Text] [Related]
18. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.
Asnacios A; Courbon F; Rochaix P; Bauvin E; Cances-Lauwers V; Susini C; Schulz S; Boneu A; Guimbaud R; Buscail L
J Clin Oncol; 2008 Feb; 26(6):963-70. PubMed ID: 18281671
[TBL] [Abstract][Full Text] [Related]
19. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma.
Leners N; Jamar F; Fiasse R; Ferrant A; Pauwels S
J Nucl Med; 1996 Jun; 37(6):916-22. PubMed ID: 8683311
[TBL] [Abstract][Full Text] [Related]
20. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
Balon HR; Goldsmith SJ; Siegel BA; Silberstein EB; Krenning EP; Lang O; Donohoe KJ;
J Nucl Med; 2001 Jul; 42(7):1134-8. PubMed ID: 11438641
[No Abstract] [Full Text] [Related]
[Next] [New Search]
